| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.1840170412 |
| P698 | PubMed publication ID | 8477964 |
| P2093 | author name string | R Poupon | |
| G Paumgartner | |||
| R E Poupon | |||
| Y Chrétien | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Synthesis of the specific monosulfates of cholic acid | Q28341114 | ||
| Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis | Q39514969 | ||
| Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism. | Q39741204 | ||
| Serum bile acid analysis | Q40144843 | ||
| Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease | Q41114391 | ||
| Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. | Q41148130 | ||
| Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients | Q41490866 | ||
| Expression of androgen receptor mRNA in human hepatocellular carcinomas and hepatoma cell lines | Q41678321 | ||
| Ursodeoxycholic acid increases low-density lipoprotein binding, uptake and degradation in isolated hamster hepatocytes | Q42161757 | ||
| Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. | Q59353134 | ||
| Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man | Q68583675 | ||
| Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids | Q68693124 | ||
| Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver | Q68843723 | ||
| Faecal steroid loss in healthy subjects during short-term treatment with ursodeoxycholic acid | Q69031613 | ||
| Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit | Q69514548 | ||
| Tauroursodeoxycholate prevents taurocholate induced cholestasis | Q70316364 | ||
| A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse-phase octadecylsilane bonded silica cartridges | Q70508994 | ||
| Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles | Q71428832 | ||
| Quantitative estimation of bile salts in serum | Q71582043 | ||
| A modified gas-liquid chromatographic procedure for the rapid determination of bile acids in biological fluids | Q72381219 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 599-604 | |
| P577 | publication date | 1993-04-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | |
| P478 | volume | 17 |
| Q42545724 | A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease |
| Q33591450 | Bile acid abnormalities in cholestatic liver diseases |
| Q34083354 | Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression |
| Q37731218 | Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid |
| Q34108895 | Biliary physiology and disease: reflections of a physician-scientist |
| Q77619556 | Cholestasis of pregnancy: ursodeoxycholic acid therapy |
| Q70670252 | Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis |
| Q33870255 | Chronic cholestatic diseases |
| Q41066462 | Clinical pharmacokinetics of therapeutic bile acids. |
| Q54176496 | Effect of cholestasis and bile acids on interferon-induced 2′, 5′-adenylate synthetase and NK cell activities |
| Q73285238 | Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis |
| Q71823028 | Effects of oral ursodeoxycholic acid in healthy cats on clinicopathological parameters, serum bile acids and light microscopic and ultrastructural features of the liver |
| Q48537205 | Extrahepatic deposition and cytotoxicity of lithocholic acid: studies in two hamster models of hepatic failure and in cultured human fibroblasts |
| Q42552188 | Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis |
| Q35734592 | Granulomatous liver disease and cholestasis |
| Q36848614 | HPLC-fluorescence determination of individual free and conjugated bile acids in human serum |
| Q74645177 | Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression |
| Q41139594 | Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. |
| Q77373443 | Influence of cholestasis on absorption of ursodeoxycholic acid |
| Q34210629 | Intrahepatic cholestasis of pregnancy. |
| Q33591454 | Mechanism of hepatoprotective action of bile salts in liver disease |
| Q35734498 | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease |
| Q34170455 | Mechanisms of cholestasis |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q37288746 | Pathogenesis and treatment of pruritus in cholestasis |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q56854243 | Primary biliary cirrhosis |
| Q84230884 | Primary biliary cirrhosis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q33869324 | Primary biliary cirrhosis: new perspectives in diagnosis and treatment |
| Q44364209 | Progressive familial intrahepatic cholestasis and hereditary anomalies lf hepatocellular metabolism of bile acids |
| Q34171026 | Progressive familial intrahepatic cholestasis. Genetic basis and treatment |
| Q57115299 | Serum Metabonomics Analysis of Liver Failure Treated by Nonbioartificial Liver Support Systems |
| Q72879601 | Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features |
| Q40974682 | The ursodeoxycholic acid story in primary biliary cirrhosis |
| Q71605603 | Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis |
| Q42699503 | Ursodeoxycholic acid and primary biliary cirrhosis |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24241945 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q77598543 | Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications |
| Q73219628 | Ursodeoxycholic acid in serum and liver tissue in patients with end-stage cholestatic liver cirrhosis |
| Q36727616 | Ursodeoxycholic acid in the treatment of liver diseases |
| Q36612947 | Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival |
| Q28377666 | Ursodeoxycholic acid therapy in hepatobiliary disease |
| Q72210615 | Ursodeoxycholic acid therapy in primary biliary cirrhosis |
| Q40457634 | Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
Search more.